摘要
目的:探讨"健肠Ⅰ号"方联合"治未病"健康管理治疗腹泻型肠易激综合征的效果,观察患者血清脑肠肽水平变化。方法:120例腹泻型肠易激综合征患者随机分为观察1组、观察2组和对照组各40例,对照组予以匹维溴铵治疗,观察1组予以健肠Ⅰ号方治疗,观察2组在健肠Ⅰ号方基础上给予"治未病"健康管理,观察3组有效率、消化道症状评分、血清脑肠肽水平变化及不良反应。结果:总有效率观察2组为97.5%,观察1组为85.0%,均高于对照组的65.0%,差异均有统计学意义(P<0.05);治疗4周后,3组消化道症状各项评分较治疗前降低,差异均有统计学意义(P<0.05),观察2组、观察1组与对照组比较,症状评分降低更明显,差异均有统计学意义(P<0.05);治疗10周后,对照组、观察1组消化道症状评分又升高,与治疗前相比差异均无统计学意义(P>0.05),而观察2组治疗10周后消化道症状评分无明显升高,与治疗前相比差异仍有统计学意义(P<0.05)。治疗4周后,3组脑肠肽水平均显著下降,与治疗前相比差异均有统计学意义(P<0.05),观察2组、观察1组与对照组比较,脑肠肽水平降低更明显,差异均有统计学意义(P<0.05);治疗10周后,对照组、观察1组脑肠肽水平又升高,与治疗前相比差异均无统计学意义(P>0.05),而观察2组治疗10周后脑肠肽水平无明显升高,与治疗前相比差异仍有统计学意义(P<0.05)。观察1组、观察2组不良反应发生率均为2.5%,低于对照组的20.0%,差异有统计学意义(P<0.05)。结论:健肠Ⅰ号方治疗腹泻型肠易激综合征的效果优于单用匹维溴铵,联合"治未病"健康管理则疗效更佳,且能有效预防复发,值得临床推广应用。
Objective:To study the clinical effect of“Jianchang NO.1”recipe combined with health management mode of“preventive treatment of disease”in the prevention and treatment of diarrhea-predominant irritable bowel syndrome.Methods:120 outpatients with diarrhea-predominant irritable bowel syndrome were randomly divided into the observation group1,observation group2 and the control group with 40 cases in each group.The control group was orally treated with pinaverium bromide,the observation group1 was given“Jianchang NO.1”recipe treatment,observation group2 was given“Jianchang NO.1”recipe combined with health management mode of“preventive treatment of disease”.Then the efficiency,gastrointestinal symptoms scores,changes of brain gut peptide levels and adverse reactions in these three groups were observed.Results:The total effective rate of the observation group2(97.5%)and group1(85.0%)were significantly higher than that of the control group(65.0%)(P<0.05);the gastrointestinal symptom score of the three groups were significantly lowered after 4 weeks of treatment(P<0.05),and the observation group2 was most obviously lowered.However,after ten weeks’follow-up observation,the gastrointestinal symptom scores of the control group and the observation group1 both rose much higher(P>0.05),comparing with the scores at the prior treatment;Also,there were significant changes in digestive symptom score in the observation group2,that compared with the score of the prior treatment(P<0.05).The levels of the gut-brain peptide in these three groups were significantly decreased after treatment(P<0.05),and the observation group2 decreased most significantly(P<0.05).The follow-up resultsat the 10th week after treatment:The brain gut peptide levels of the control group and observation group1 were not significantly higher than the levels of the prior treatment(P>0.05),but the brain-gut peptide levels of the observation group2 didn’t significantly change when compared with the levels after the prior treatment(P<0.05).The
作者
葛飞
余利华
季瑜
朱时林
田祖成
梅莉
代海峰
葛乃建
GE Fei;YU Lihua;JI Yu;ZHU Shilin;TIAN Zucheng;MEI Li;DAI Haifeng;GE Naijian(Department of Gastroenterology,Hai’an County Hospital of Traditiona Chinese Medicine,Jiangsu 226600;Department of Gastroenterology,Wuxi Hospital of Integrated Traditional Chinese and Western Medicine;Minimally Invasive Interventional Center,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University)
出处
《交通医学》
2018年第1期6-9,共4页
Medical Journal of Communications
基金
国家自然科学基金青年科学基金项目(81603578)
江苏省自然科学基金青年科学基金项目(BK20151008)
江苏省中医药局科技项目(YB2017066)
关键词
肠易激综合征
健肠Ⅰ号
治未病
脑肠轴
irritable bowel syndrome
Jianchang NO.1 recipe
preventive treatment of disease
brain gut axis
